Opsens - 50,000 patients diagnosed with the OptoWire

QUEBEC CITY, Nov. 1, 2018 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) has reached an important milestone with more than 50,000 patients assessed with the OptoWire™, a pressure guidewire used to measure Fractional Flow Reserve ("FFR") to diagnose and treat cardio vascular disease.

The use of pressure guidewires to measure FFR for the evaluation of coronary blockages has grown over the years and is now considered the gold standard. Clinical data have shown a reduction in mortality in patients assessed using this technique.

As Societies of Cardiology are recommending expanding the use of pressure guidewires and physiology assessments, Opsens has scaled up manufacturing to respond to the growing demand for the OptoWire in its main markets, namely Japan, the United States, Europe and Canada, and to expand its reach to new geographies.

"This milestone is a testament to the quality of our product, of our team and of our vision to take on the challenge to bring a second-generation fiber optic technology pressure guidewire to the market," said Louis Laflamme, President and CEO. "Our customers are delighted by the benefits brought on by the OptoWire and we are encouraged by their excellent feedback in terms of diagnostic accuracy as well as the time-saving and cost-effectiveness it can provide to the procedure."

Opsens differentiates from the competition by the performance of the OptoWire in terms of vessel accessibility, as well as for the reliability and the accuracy of its second-generation fiber optic sensor.

Market adoption of the OptoWire has grown at a rapid pace and Opsens is now commercializing the OptoWire in more than 30 countries, with especially robust growth in the United States and Japan.

Laflamme concluded by sharing the unique passion that lives at Opsens: "Passing the 50,000 units sold, especially when more than half of these sales were completed in the last 12 months is a tremendous achievement. More than a number of units sold, our team gets pride in supporting physicians to provide accurate diagnostic and proper treatment to their patients."

About Opsens Inc. (www.opsens.com or www.opsensmedical.com)

Opsens focuses mainly on the measure of FFR and dPR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a 2^nd-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 50,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

SOURCE OPSENS Inc.

For further information: Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333; Robin Villeneuve, CPA, CA, Chief Financial Officer, 418.781.0333

Related Links

www.opsens.com